Thursday's tips round-up: Imperial Innovations, Barratt, Autonomy

10th Jun 2010 07:42

Imperial Innovations is starting to make strong gains on exits from its portfolio, selling Thiakis, the developer of an anti-obesity drug, to America's Wyeth and, last week, disposing of Respivert, the maker of a respiratory treatment, to an offshoot of Johnson & Johnson. At 474½p, tuck away.The Independent think market sentiment is far too fragile and Barratt and its peers, through no fault of their own, could continue to weaken in the near term. Sell.Autonomy has also moved into the social media space with the recent announcement of software designed to monitor, govern and protect organisations as employees' social media habits increase. Panmure Gordon has the stock on a price 16.4 times estimated 2011 earnings, and given its strength and edge in the sector, we reckon it is worth having to add more to the portfolio. Buy, says the Independent.The outlook for overseas business is uncertain and dependent on the economy. So, wait until Dewhurst shares have settled at a lower level then buy. You can at least be sure that the company's progress reports will be reliable, says the Independent.IG continues to grow at home and abroad ? especially in Australia, Germany and France, now sizeable markets. Such expansion also brings steadily higher operating margins: aside from the initial marketing expenditure, IG can add new customers at little extra cost. Even after yesterday's 39½p rise to 431¾p ? or a multiple of 12 times earnings and offering a 4 per cent dividend yield ? the shares look unstretched. Hold, says the Times. Telgraph also says hold.Please note: Digital Look provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look cannot take any responsibility for information provided by third parties. This is for your general information only as not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information.